DDPred helps users determine and manage the issues related to drug-drug interactions. This increases R&D productivity and decreases the risk of attrition during the clinical phases of drug development

Identify the most relevant drug drug interaction studies to conduct

DDPred generates a comprehensive list of the AUC ratios of drug-drug interactions with an NCE, helping identify the drugs that are most likely to have clinically relevant interactions.

Identify the most relevant pharmacogenetic studies to conduct

By quantitatively predicting the impact of CYP polymorphisms, DDPred helps identify the genotypes that are most at risk of over- or underexposure.

Better inform the design of Phase II and Phase III studies

DDPred predictions help define inclusion and non-inclusion criteria related to co-medications and cytochrome genetic polymorphisms.

Increase the inclusion rate of patients in Phase III trials

DDPred helps the user anticipate the dose adaptations that may be needed due to the effects of co-medications and/or CYP polymorphisms. This can expand inclusion criteria and reduce exclusion criteria.

Simplify the writing of the Precautions section

Leverage the lists of positive and negative interactions generated by DDPred to support the writing of the precautions section of drug applications.

Reinforce the interpretation of Adverse Event Reports

Adverse Events can be caused by drug overexposure due to the rare effects of drug combinations and/or CYP polymorphisms. DDPred helps evaluate the likelihood of Adverse Events for each drug taken by the patient.

Optimize the clinical phases of your drug development

Use of simulations such as the quantitative predictions generated by DDPred helps reducing the number of clinical studies to be conducted and/or the number of patients to be recruited.

Want to know more about the features?

Check the DDPred’s User’s Guide to see all features.

Want to see pricing

DDPred pricing depends on the user’s choice of features